SpringWorks Therapeutics, Inc. SWTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

57/100

4/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

SpringWorks Therapeutics, Inc. (SWTX) generated $-68.76M in operating cash flow for quarter ending 2025-03-31. After capital expenditures of $30K, free cash flow was $-68.79M.

Free cash flow margin was -140.1% of revenue. Cash conversion ratio was 0.83x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (70/100, Pass) — $-68.79M (-140.1% margin) supports a durable competitive advantage
INCOME (10/100) — Cash conversion ratio was 0.83x suggests some earnings are non-cash items

Overall SharesGrow Score: 57/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score

57/100

SG Score

View full scorecard →

✓

VALUE

90/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

73/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✓

MOAT

70/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

SpringWorks Therapeutics, Inc. Cash Flow History

Metric	TTM	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024
Operating Cash Flow	$-165.43M	$-68.76M	$-29.5M	$-25.38M	$-41.79M
Capital Expenditure	$-8.9M	$-30K	$-6.05M	$9.4M	$-12.23M
Free Cash Flow	$-174.33M	$-68.79M	$-35.55M	$-15.98M	$-54.02M